Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Summit Therapeutics Q1 EPS $(0.06) Up From $(1.43) YoY; Exits Q1 With Cash & Equivalents Worth $157M

Author: Benzinga Newsdesk | May 01, 2024 07:04am
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.06) per share. This is a 95.8 percent increase over losses of $(1.43) per share from the same period last year.

Posted In: SMMT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist